Janone inc. acquires worldwide, exclusive license for promising treatment of peripheral arterial disease (pad)

Janone inc. announced a licensing agreement for tv1001sr, a treatment for peripheral artery disease, commonly called pad. the agreement with lsu health shreveport, uab research foundation, and theravasc inc., gives janone a worldwide, exclusive license for tv1001sr along with a portfolio of 30 patents and other intellectual property relating to the sustained release of sodium nitrite. the company anticipates tv1001sr will be a treatment for those with pad, an often painful disease affecting more than 200 million people worldwide and 8.5 million in the united states.
JAN Ratings Summary
JAN Quant Ranking